Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy
- 1 May 1995
- journal article
- case report
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 82 (5) , 886-890
- https://doi.org/10.3171/jns.1995.82.5.0886
Abstract
A 14-year-old girl presented with a rapidly growing, invasive prolactin-producing pituitary tumor that failed to respond to dopamine agonist medication. Histological, immunocytochemical, and ultrastructural studies of the surgically removed tissue revealed a pleomorphic, chromophobic, or slightly acidophilic pituitary tumor that was immunoreactive for prolactin and that, according to electron microscopy, consisted of atypical lactotrophs showing no evidence of cell shrinkage. In situ hybridization demonstrated large amounts of prolactin messenger ribonucleic acid (mRNA), moderate amounts of estrogen receptor mRNA and dopamine (D2) receptor mRNA, and an absence of growth hormone mRNA in the tumor cells. Because D2 receptor mRNA was present in the tumor, causes other than D2 receptor loss may have been responsible for the resistance of the lactotrophs to dopamine agonist administration.Keywords
This publication has 18 references indexed in Scilit:
- The Importance of p53 Gene Alterations in Human Cancer: Is There More Than Circumstantial Evidence?JNCI Journal of the National Cancer Institute, 1993
- Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrenceJournal of Neurosurgery, 1993
- Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sectionsThe Journal of Pathology, 1992
- Dopamine agonists and pituitary tumor shrinkageEndocrine Reviews, 1992
- D2 Dopaminergic Receptors: Normal and Abnormal Transduction MechanismsHormone Research, 1992
- Prolactinomas and Resistance to Dopamine AgonistsHormone Research, 1992
- Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomasClinical Endocrinology, 1991
- Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasmsThe Journal of Pathology, 1990
- Management of ProlactinomasAnnual Review of Medicine, 1989